MicroRNA Expression Profiling

microRNA profiling with febit’s miRNA Biochip assay

Automated miRNA profiling with febit’s miRNA Biochips

febit’s Genomic Services routinely use the established miRNA Biochip assay for biomarker studies, applying the assay to any disease of interest.

  • highly sensitive analysis of limited clinical sample material, like body fluids
  • established protocol and Biochips for routine sample testing
  • development of diagnostic biomarker signatures
  • multiplex testing
  • highly reproducible biomarker test results
  • Up-to-date array content: Instant access to the latest miRBase release
  • Flexible Geniom miRNA Biochip customization with novel and proprietary sequences

Technology background

With the Microfluidic Primer Extension Assay (MPEA) for miRNA profiling, febit’s automated microarray platform provides an established protocol for routine sample testing.

  • On-chip labeling for simplified sample testing
  • Minimal sample amounts
  • Test requires no prior enrichment, amplification or labeling
  • Unbeatable sensitivity and specificity
Genomic Services: febit’s miRNA profiling workflow

The unique MPEA uses unlabeled RNA samples for hybridization. In a second step, the specific enzymatic elongation of the bound miRNAs takes place. This method reduces the required sample amount to a minimum, taking into account that clinical samples are typically limited.

Complete automation of Biochip processing on the Geniom RT Analyzer and integrated bioinformatics solutions guarantee quick test results. In addition to rapid turn-around time and increased efficiency, automation yields consistency in miRNA Biochip processing conditions which translate into highly reproducible biomarker test results.

Microfluidic microarray systems, like Geniom Biochips, offer the required flexibility to be instantly adapted to new sequence information. Validated and optimized capture probes for every biomarker molecule are directly synthesized within the microchannels of the Biochip, enabling on-the-fly production of up-to-date biomarker tests. Additionally, probe content can easily be customized to include proprietary, predicted or mutated miRNA sequences.